Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Abstract Patient-reported outcomes data assessing patients’ experience of immunotherapy treatment burden in potentially curable early-stage triple-negative breast cancer (TNBC) are lacking. These patient-reported data inform clinical benefit and decision-making for adding atezolizumab to neoadjuvant...

Full description

Bibliographic Details
Main Authors: Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00457-3

Internet

https://doi.org/10.1038/s41523-022-00457-3

Similar Items